Stock Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson Faces Uphill Battle At FDA Advisory Panel

[at Forbes] – The third time may not be the charm. Twice before the FDA has turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson’s . . . → Read More: Stock Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson Faces Uphill Battle At FDA Advisory Panel